Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2001

View Archived Issues

HIV vaccine candidate evaluated in phase I trials

Lundbeck's psychopharmacological drug pipeline

Neurological drugs in Lundbeck's pipeline

Analysis of study results with topiramate in diabetic neuropathic pain

Human testing of injectable urethral bulking agent in progress

Organon plans to continue development of the Ampakine Org-24448

Novo Nordisk's rapid-acting insulin analogue now available in U.S.

More flexible and personalized therapy now possible with NeoRecormon

TAK-083 highly effective in the laboratory and in animals against H. pylori

Free I2 as an effective oxidant in human sperm

ATLAS study: sequence of events in heart failure progression and protective effects of lisinopril

Allovectin-7 phase III registration trial in metastatic melanoma now fully enrolled

Longer acting treatment for anemia in chronic renal failure cleared for U.S. launch

Amgen elects not to develop Guilford's neuroimmunophilin ligands

Muscarinic receptor binding profile of YM-905 correlated with pharmacological activity

Tiagabine as a potential treatment option for overactive bladder

Taxanes with potent antitumor activity reported by Florida State

New antimycobacterial compounds from Genzyme interfere with cell wall biosynthesis

Bayer and Millennium announce identification of 140 disease-relevant drug targets

Nippon Kayaku prepares new agents for use in photochemical therapy of tumors

Pharmos expands pivotal phase III trial of dexanabinol into U.K.

First evidence that overexpression of dopamine D2 receptor reduces alcohol intake

Erythromycin derivatives identified by Hokuriku active against H. pylori

Two series of factor Xa inhibitors disclosed recently by Cor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...